Wedbush Securities’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Wedbush Securities’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-276,530	Closed	-$5K	–	977
2018 Q4	$5K	Buy	276,530 +190,000	+220%	+$39.4K	﹤0.01%	831
2018 Q3	$18K	Hold	86,530	–	–	﹤0.01%	890
2018 Q2	$22K	Hold	86,530	–	–	﹤0.01%	863
2018 Q1	$22K	Hold	86,530	–	–	﹤0.01%	806
2017 Q4	$27K	Buy	86,530 +25,000	+41%	+$8.51K	﹤0.01%	837
2017 Q3	$23K	Buy	61,530 +24,030	+64%	+$11.7K	﹤0.01%	823
2017 Q2	$32K	Buy	+37,500	New	+$61.3K	﹤0.01%	816

Wedbush Securities's IMUC Position: Q1 2019 in Review

Wedbush Securities sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q1 2019, closing a stake of 276,530 shares — an estimated $5K sold.

Wedbush Securities first reported a position in IMUC in Q2 2017 and held it in 7 quarters. The position peaked at $32K in Q2 2017. 1 fund tracked by Wall St. Rank holds IMUC as of Q1 2019.

Wedbush Securities reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q1 2019 after selling out during the quarter.
Wedbush Securities sold 276,530 ImmunoCellular Therapeutics, Ltd. shares in Q1 2019, an estimated $5K.
Wedbush Securities first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2017 and held it in 7 quarters.
Wedbush Securities's ImmunoCellular Therapeutics, Ltd. position peaked at $32K in Q2 2017.
1 fund tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q1 2019.

Based on Wedbush Securities's 13F filing for Q1 2019, filed 17 Apr 2019.